Skip to main content
. 2017 Sep 6;8(16):3122–3129. doi: 10.7150/jca.22046

Table 2.

Correlations between combined fascin and BRMS1 expression status and clinicopathological features

Parameter Fascin-/BRMS1+ Fascin+/BRMS1- p-value
n=99 n=18
Age <50 61 (61.6) 13 (72.2) 0.439
≥50 38 (38.4) 5 (27.8)
Tumor stage pT1 49 (49.5) 8 (44.4) 0.800
pT2-3 50 (50.5) 10 (55.6)
Nodal stage pN0 49 (49.5) 14 (77.8) 0.038
pN1-3 50 (50.5) 4 (22.2)
AJCC stage I 79 (79.8) 15 (83.3) 1.000
II-III 20 (20.2) 3 (16.7)
Histologic grade 1 21 (21.2) 0 (0.0) 0.040
2/3 78 (78.8) 18 (100.0)
Nuclear grade 1 44 (44.4) 2 (11.1) 0.008
2/3 55 (55.6) 16 (88.9)
Lymphovasculr invasion Absent 40 (40.4) 10 (55.6) 0.302
Present 59 (59.6) 8 (44.4)
ER Positive 75 (75.8) 0 (0.0) <0.001
Negative 24 (24.2) 18 (100.0)
PR Positive 59 (59.6) 0 (0.0) <0.001
Negative 40 (40.4) 18 (100.0)
HER2 Negative 73 (73.7) 17 (94.4) 0.069
Positive 26 (26.3) 1 (5.6)
Intrinsic subtype Luminal A 63 (63.6) 0 (0.0) < 0.001
Luminal B 13 (13.1) 0 (0.0)
HER2 13 (13.1) 1 (5.6)
Triple-negative 10 (10.1) 17 (94.4)
Tumor recurrence Present 83 (83.8) 16 (88.9) 0.738
Patients death Present 12 (12.1) 3 (16.7) 0.700